论文部分内容阅读
The combination of doxorubicin(DOX)with sorafenib(SOR)has been proved to be an effective strategy to enhance anti-hepatocellular carcinoma(HCC)efficiency [1].However,respective in vivo pharmacokinetic profiles and different endocytosis capacities of these two drugs greatly hinder their current application [2].To solve these problems and enhance the anti-HCC efficacy,the tumor-targeting poly(lactic-co-glycolic acid)(PLGA)-lecithin-poly(ethylene glycol)(PEG)core-shell nanoparticles(NPs)decorated with a tumor-penetrating peptide iRGD were developed for DOX and SOR co-delivery.